Maurice R. Ferré MD is CEO and Chairman of the Board of Directors at Insightec, a global medical technology innovator of incisionless surgery. Dr. Ferré brings over 20 years of experience in the medical device industry. Before Insightec, Dr. Ferré served as Chairman of the Board and CEO of MAKO Surgical Corp, a transformational robotic surgical company that he co-founded in 2004. The company was IPO’d in 2008 and sold to Stryker Corp. for $1.65 billion in 2013. Prior to MAKO, Dr. Ferré was Founder, CEO and President of Visualization Technology Inc. (1993-2002). VTI became the world leader in image guided surgery for ENT, cranial and orthopedic procedures. The Company was acquired by GE Healthcare in 2002.
Dr. Ferré received his Doctor of Medicine and Master of Public Health from Boston University in 1992. He was also the recipient of the prestigious Ernest & Young 2007 Entrepreneur of the Year Award. Dr Ferre is currently active on the following boards: Advamed, The Everglades Foundation and Boston University.
Focused ultrasound, essentially concentrated sound waves, have been used in early-stage clinical trials to temporarily disrupt the blood-brain barrier, creating a window of time where a therapeutic treatment could be delivered in a targeted manner. The potential impact of this advancement is enormous.
Healthcare practitioners will integrate new medtech tools into clinical practice and create more effective and safe procedures globally, but doing so successfully requires the medtech industry to address certain acute healthcare issues.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.